Psoriasis Trial, Recruiting NCT07532486 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Psoriasis
Back to Psoriasis

Psoriasis Trial, Recruiting

NCT07532486
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with plaque-type psoriasis (with or without psoriatic arthritis) for at least 6 months before the study begins — with or without joint involvement.
  • People whose psoriasis is considered moderate to severe, based on standard skin assessment scores measured at the start of the study.
  • People whose psoriasis is considered appropriate for systemic (whole-body) treatment, whether or not they have previously received biologic medications.
  • Women who could become pregnant must have a negative pregnancy test at screening and at the start of the study, and must agree to pregnancy testing before each injection.
  • People who have no signs or symptoms suggesting active tuberculosis (TB), based on medical history and physical examination.
  • People who agree not to receive a BCG vaccine during the study or within 12 months after the last dose of the study drug.
  • People who agree not to receive any live virus or live bacterial vaccine during the study or within 3 months after the last dose of the study drug.
  • People who have read and signed a consent form showing they understand the study and are willing to take part.

Who may not be able to join:

  • People who have a non-plaque form of psoriasis, such as erythrodermic, guttate, or pustular psoriasis.
  • People whose psoriasis appears to have been caused or worsened by certain medications, such as beta-blockers, calcium channel blockers, or lithium.
  • People with a history of, or current signs of, significant liver or kidney problems, or serious uncontrolled conditions affecting the heart, blood vessels, lungs, digestive system, hormones, nervous system, blood, joints, mental health, or metabolism.
  • People who have had a cancer diagnosis within the past 5 years, with some exceptions for certain treated skin cancers or cervical conditions with no signs of return — confirm specific exceptions with the trial site.
  • People with a history of lymphoma or other diseases affecting the lymph system, or signs that may suggest such a condition, such as swollen lymph nodes or an enlarged spleen.
  • People with a history of ongoing, repeated, or chronic infections, including recurrent sinus or lung infections, recurrent urinary tract infections, certain fungal infections, or open or infected skin wounds.
  • People who test positive for hepatitis B, or who test positive for hepatitis C antibodies, unless specific conditions around prior treatment and test results have been met (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86 15088611296

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
10 July 2024
Est. completion
10 July 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI)-90 Response at Week 86; Percentage of Participants Who Achieve an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 86; Number of Participants with Adverse Events (AE); Number of Participants with Change from Baseline in Laboratory Abnormalities; Number of Participants with Abnormalities of Electrocardiogram (ECG); Number of Participants with Change from Baseline in Vital Signs; Number of Participants with Change from Baseline in Physical Examination; Number of Participants with...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov